60 Degrees Pharmaceuticals (SXTP) Earnings Date, Estimates & Call Transcripts $0.87 -0.05 (-5.41%) (As of 11/21/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends 60 Degrees Pharmaceuticals Latest Earnings SummaryLatest Q2 2024 Earnings DateAug. 14EstimatedActual EPS (Aug. 14) -$4.23 Missed By -$1.44 Consensus EPS (Aug. 14) -$2.79 60 Degrees Pharmaceuticals announced Q2 2024 earnings on August 14, 2024, reporting an EPS of -$4.23, which missed the consensus estimate of -$2.79 by $1.44. Quarterly revenue was reported to be $0.13 million, above analysts' expectations of $0.11 million. With a trailing EPS of -$10.08, 60 Degrees Pharmaceuticals' earnings are expected to grow next year, from ($5.09) to ($0.61) per share. Get 60 Degrees Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSXTP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SXTP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Weiss RatingsThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. 60 Degrees Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.16-$0.16-$0.16Q2 20241-$0.33-$0.33-$0.33Q3 20241-$0.93-$0.93-$0.93Q4 20241-$0.97-$0.97-$0.97FY 20244($2.39)($2.39)($2.39) 60 Degrees Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks8/14/2024Q2 2024-$2.79-$4.23 -$1.44-$4.23$0.11M$0.13M5/15/2024Q1 2024-$0.16$0.03+$0.19$0.03-$0.08M4/1/2024Q4 2023--$0.44 -$0.44-$0.44$0.06M-$0.10M11/20/2023Q3 2023-$0.26-$0.30 -$0.04-$1.37$0.08M$0.06M8/25/2023Q2 2023--$1.40 -$1.40-$1.40-$0.06M 60 Degrees Pharmaceuticals Earnings - Frequently Asked Questions When did 60 Degrees Pharmaceuticals announce their last quarterly earnings? 60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its quarterly earning data on Wednesday, August 14, 2024. Learn more on SXTP's earnings history. Did 60 Degrees Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, 60 Degrees Pharmaceuticals (NASDAQ:SXTP) missed the analysts' consensus estimate of ($2.79) by $1.44 with a reported earnings per share (EPS) of ($4.23). Learn more on analysts' earnings estimate vs. SXTP's actual earnings. How much revenue does 60 Degrees Pharmaceuticals generate each year? 60 Degrees Pharmaceuticals (NASDAQ:SXTP) has a recorded annual revenue of $250,000.00. How much profit does 60 Degrees Pharmaceuticals generate each year? 60 Degrees Pharmaceuticals (NASDAQ:SXTP) has a recorded net income of -$3.77 million. SXTP has generated -$10.08 earnings per share over the last four quarters. What is 60 Degrees Pharmaceuticals's EPS forecast for next year? 60 Degrees Pharmaceuticals's earnings are expected to grow from ($5.09) per share to ($0.61) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Galecto Earnings Results Biora Therapeutics Earnings Results Syros Pharmaceuticals Earnings Results ABVC BioPharma Earnings Results Can-Fite BioPharma Earnings Results Edesa Biotech Earnings Results Eyenovia Earnings Results GT Biopharma Earnings Results Evoke Pharma Earnings Results Adial Pharmaceuticals Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report The #1 Crypto for AI (Ad)We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. This page (NASDAQ:SXTP) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
